Global Pulmonary Arterial Hypertension (PAH) Market Research Report 2022

Pulmonary Arterial Hypertension (PAH) market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Pulmonary Arterial Hypertension (PAH) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

    Prostacyclin and Prostacyclin Analogs

    SGC Stimulators

ERA

    PDE-5

Segment by Application

    Hospital

    Clinic

By Region

    North America

        United States

        Canada

    Europe

        Germany

        France

UK

        Italy

        Russia

        Nordic Countries

        Rest of Europe

    Asia-Pacific

        China

        Japan

        South Korea

        Southeast Asia

        India

        Australia

        Rest of Asia

    Latin America

        Mexico

        Brazil

        Rest of Latin America

    Middle East & Africa

        Turkey

        Saudi Arabia

UAE

        Rest of MEA

By Company

    Actelion

    Gilead Sciences

    United Therapeutics

    GlaxoSmithKline

    Pfizer

    Bayer

    Arena

1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 Prostacyclin and Prostacyclin Analogs
        1.2.3 SGC Stimulators
        1.2.4 ERA
        1.2.5 PDE-5
    1.3 Market by Application
        1.3.1 Global Pulmonary Arterial Hypertension (PAH) Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Hospital
        1.3.3 Clinic
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Pulmonary Arterial Hypertension (PAH) Market Perspective (2017-2028)
    2.2 Pulmonary Arterial Hypertension (PAH) Growth Trends by Region
        2.2.1 Pulmonary Arterial Hypertension (PAH) Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Pulmonary Arterial Hypertension (PAH) Historic Market Size by Region (2017-2022)
        2.2.3 Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Region (2023-2028)
    2.3 Pulmonary Arterial Hypertension (PAH) Market Dynamics
        2.3.1 Pulmonary Arterial Hypertension (PAH) Industry Trends
        2.3.2 Pulmonary Arterial Hypertension (PAH) Market Drivers
        2.3.3 Pulmonary Arterial Hypertension (PAH) Market Challenges
        2.3.4 Pulmonary Arterial Hypertension (PAH) Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Revenue
        3.1.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Revenue (2017-2022)
        3.1.2 Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Players (2017-2022)
    3.2 Global Pulmonary Arterial Hypertension (PAH) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Pulmonary Arterial Hypertension (PAH) Revenue
    3.4 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio
        3.4.1 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Pulmonary Arterial Hypertension (PAH) Revenue in 2021
    3.5 Pulmonary Arterial Hypertension (PAH) Key Players Head office and Area Served
    3.6 Key Players Pulmonary Arterial Hypertension (PAH) Product Solution and Service
    3.7 Date of Enter into Pulmonary Arterial Hypertension (PAH) Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Pulmonary Arterial Hypertension (PAH) Breakdown Data by Type
    4.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Type (2017-2022)
    4.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Type (2023-2028)
5 Pulmonary Arterial Hypertension (PAH) Breakdown Data by Application
    5.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Application (2017-2022)
    5.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Pulmonary Arterial Hypertension (PAH) Market Size (2017-2028)
    6.2 North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022)
    6.3 North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size (2017-2028)
    7.2 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022)
    7.3 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size (2017-2028)
    8.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022)
    8.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Pulmonary Arterial Hypertension (PAH) Market Size (2017-2028)
    9.2 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022)
    9.3 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size (2017-2028)
    10.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022)
    10.3 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 Actelion
        11.1.1 Actelion Company Detail
        11.1.2 Actelion Business Overview
        11.1.3 Actelion Pulmonary Arterial Hypertension (PAH) Introduction
        11.1.4 Actelion Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
        11.1.5 Actelion Recent Development
    11.2 Gilead Sciences
        11.2.1 Gilead Sciences Company Detail
        11.2.2 Gilead Sciences Business Overview
        11.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Introduction
        11.2.4 Gilead Sciences Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
        11.2.5 Gilead Sciences Recent Development
    11.3 United Therapeutics
        11.3.1 United Therapeutics Company Detail
        11.3.2 United Therapeutics Business Overview
        11.3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Introduction
        11.3.4 United Therapeutics Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
        11.3.5 United Therapeutics Recent Development
    11.4 GlaxoSmithKline
        11.4.1 GlaxoSmithKline Company Detail
        11.4.2 GlaxoSmithKline Business Overview
        11.4.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Introduction
        11.4.4 GlaxoSmithKline Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
        11.4.5 GlaxoSmithKline Recent Development
    11.5 Pfizer
        11.5.1 Pfizer Company Detail
        11.5.2 Pfizer Business Overview
        11.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Introduction
        11.5.4 Pfizer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
        11.5.5 Pfizer Recent Development
    11.6 Bayer
        11.6.1 Bayer Company Detail
        11.6.2 Bayer Business Overview
        11.6.3 Bayer Pulmonary Arterial Hypertension (PAH) Introduction
        11.6.4 Bayer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
        11.6.5 Bayer Recent Development
    11.7 Arena
        11.7.1 Arena Company Detail
        11.7.2 Arena Business Overview
        11.7.3 Arena Pulmonary Arterial Hypertension (PAH) Introduction
        11.7.4 Arena Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
        11.7.5 Arena Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Prostacyclin and Prostacyclin Analogs
    Table 3. Key Players of SGC Stimulators
    Table 4. Key Players of ERA
    Table 5. Key Players of PDE-5
    Table 6. Global Pulmonary Arterial Hypertension (PAH) Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 7. Global Pulmonary Arterial Hypertension (PAH) Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 8. Global Pulmonary Arterial Hypertension (PAH) Market Size by Region (2017-2022) & (US$ Million)
    Table 9. Global Pulmonary Arterial Hypertension (PAH) Market Share by Region (2017-2022)
    Table 10. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 11. Global Pulmonary Arterial Hypertension (PAH) Market Share by Region (2023-2028)
    Table 12. Pulmonary Arterial Hypertension (PAH) Market Trends
    Table 13. Pulmonary Arterial Hypertension (PAH) Market Drivers
    Table 14. Pulmonary Arterial Hypertension (PAH) Market Challenges
    Table 15. Pulmonary Arterial Hypertension (PAH) Market Restraints
    Table 16. Global Pulmonary Arterial Hypertension (PAH) Revenue by Players (2017-2022) & (US$ Million)
    Table 17. Global Pulmonary Arterial Hypertension (PAH) Market Share by Players (2017-2022)
    Table 18. Global Top Pulmonary Arterial Hypertension (PAH) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension (PAH) as of 2021)
    Table 19. Ranking of Global Top Pulmonary Arterial Hypertension (PAH) Companies by Revenue (US$ Million) in 2021
    Table 20. Global 5 Largest Players Market Share by Pulmonary Arterial Hypertension (PAH) Revenue (CR5 and HHI) & (2017-2022)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Pulmonary Arterial Hypertension (PAH) Product Solution and Service
    Table 23. Date of Enter into Pulmonary Arterial Hypertension (PAH) Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Pulmonary Arterial Hypertension (PAH) Market Size by Type (2017-2022) & (US$ Million)
    Table 26. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2017-2022)
    Table 27. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 28. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2023-2028)
    Table 29. Global Pulmonary Arterial Hypertension (PAH) Market Size by Application (2017-2022) & (US$ Million)
    Table 30. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Application (2017-2022)
    Table 31. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 32. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Application (2023-2028)
    Table 33. North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022) & (US$ Million)
    Table 34. North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028) & (US$ Million)
    Table 35. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022) & (US$ Million)
    Table 36. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028) & (US$ Million)
    Table 37. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2017-2022) & (US$ Million)
    Table 38. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2023-2028) & (US$ Million)
    Table 39. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022) & (US$ Million)
    Table 40. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028) & (US$ Million)
    Table 41. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022) & (US$ Million)
    Table 42. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028) & (US$ Million)
    Table 43. Actelion Company Detail
    Table 44. Actelion Business Overview
    Table 45. Actelion Pulmonary Arterial Hypertension (PAH) Product
    Table 46. Actelion Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022) & (US$ Million)
    Table 47. Actelion Recent Development
    Table 48. Gilead Sciences Company Detail
    Table 49. Gilead Sciences Business Overview
    Table 50. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Product
    Table 51. Gilead Sciences Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022) & (US$ Million)
    Table 52. Gilead Sciences Recent Development
    Table 53. United Therapeutics Company Detail
    Table 54. United Therapeutics Business Overview
    Table 55. United Therapeutics Pulmonary Arterial Hypertension (PAH) Product
    Table 56. United Therapeutics Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022) & (US$ Million)
    Table 57. United Therapeutics Recent Development
    Table 58. GlaxoSmithKline Company Detail
    Table 59. GlaxoSmithKline Business Overview
    Table 60. GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Product
    Table 61. GlaxoSmithKline Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022) & (US$ Million)
    Table 62. GlaxoSmithKline Recent Development
    Table 63. Pfizer Company Detail
    Table 64. Pfizer Business Overview
    Table 65. Pfizer Pulmonary Arterial Hypertension (PAH) Product
    Table 66. Pfizer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022) & (US$ Million)
    Table 67. Pfizer Recent Development
    Table 68. Bayer Company Detail
    Table 69. Bayer Business Overview
    Table 70. Bayer Pulmonary Arterial Hypertension (PAH) Product
    Table 71. Bayer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022) & (US$ Million)
    Table 72. Bayer Recent Development
    Table 73. Arena Company Detail
    Table 74. Arena Business Overview
    Table 75. Arena Pulmonary Arterial Hypertension (PAH) Product
    Table 76. Arena Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022) & (US$ Million)
    Table 77. Arena Recent Development
    Table 78. Research Programs/Design for This Report
    Table 79. Key Data Information from Secondary Sources
    Table 80. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Pulmonary Arterial Hypertension (PAH) Market Share by Type: 2021 VS 2028
    Figure 2. Prostacyclin and Prostacyclin Analogs Features
    Figure 3. SGC Stimulators Features
    Figure 4. ERA Features
    Figure 5. PDE-5 Features
    Figure 6. Global Pulmonary Arterial Hypertension (PAH) Market Share by Application in 2021 & 2028
    Figure 7. Hospital Case Studies
    Figure 8. Clinic Case Studies
    Figure 9. Pulmonary Arterial Hypertension (PAH) Report Years Considered
    Figure 10. Global Pulmonary Arterial Hypertension (PAH) Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 11. Global Pulmonary Arterial Hypertension (PAH) Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Pulmonary Arterial Hypertension (PAH) Market Share by Region: 2021 VS 2028
    Figure 13. Global Pulmonary Arterial Hypertension (PAH) Market Share by Players in 2021
    Figure 14. Global Top Pulmonary Arterial Hypertension (PAH) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension (PAH) as of 2021)
    Figure 15. The Top 10 and 5 Players Market Share by Pulmonary Arterial Hypertension (PAH) Revenue in 2021
    Figure 16. North America Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 17. North America Pulmonary Arterial Hypertension (PAH) Market Share by Country (2017-2028)
    Figure 18. United States Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 19. Canada Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. Europe Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Europe Pulmonary Arterial Hypertension (PAH) Market Share by Country (2017-2028)
    Figure 22. Germany Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. France Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. U.K. Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Italy Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Russia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Nordic Countries Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Share by Region (2017-2028)
    Figure 30. China Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Japan Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. South Korea Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. India Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Australia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Latin America Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Latin America Pulmonary Arterial Hypertension (PAH) Market Share by Country (2017-2028)
    Figure 38. Mexico Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Brazil Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Share by Country (2017-2028)
    Figure 42. Turkey Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Actelion Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
    Figure 45. Gilead Sciences Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
    Figure 46. United Therapeutics Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
    Figure 47. GlaxoSmithKline Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
    Figure 48. Pfizer Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
    Figure 49. Bayer Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
    Figure 50. Arena Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
    Figure 51. Bottom-up and Top-down Approaches for This Report
    Figure 52. Data Triangulation
    Figure 53. Key Executives Interviewed

Name*

Email ID*

Company*

Phone (With Country Code)*

What is/are your question(s)?:

Publisher: QY Research

Related Reports

Global Viral Transport Media Market Analysis and Forecast, 2022-2028

Global Ultrasonic Technology Market Analysis and Forecast, 2022-2028

Global Specimen Radiography System Market Analysis and Forecast, 2022-2028

Global Single-use Medical Devices Market Analysis and Forecast, 2022-2028

Global Sepsis Diagnostics Market Analysis and Forecast, 2022-2028

Why Market Study Report?

Best Price for Reports
Large Report Database
Easily Customize Reports
24/7 Email & Phone Support